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EDITORIAL
Predicting the outcome of human renal diseases by
gene expression profiling: Myth or reality?
All over the world millions of people are affected by
chronic renal failure, leading to immense suffering and
an increasing economic burden. In 1998, the number of
patients with end-stage renal failure (ESRF) was approx-
imately 600,000 in the European Union and the United
States [1, 2]. It is anticipated that this number will dou-
ble by the end of 2010. The incidence of ESRF is indeed
being augmented by an annual rate of 6% to 8% due to
a dramatic increase in the number of patients with type 2
diabetes and vascular diseases, and to the increasing age
of the population. Dialysis will remain the only option for
the majority of the patients because the supply of donor
organs for transplantation is so limited, and because many
patients are now no longer suitable for transplantation
because of age and deteriorated condition. It has been
calculated that a 30% reduction in the rate of decline of
renal function in patients with moderate-to-severe renal
failure would translate into cumulative direct health care
savings of more than $60 billion dollars by the year 2010
in the United States [3]. This emphasizes the urgent need
to minimize the number of people developing chronic re-
nal failure (CRF), and this can only be achieved by more
effective treatment of the diseases that cause it.
CRF can be caused by diseases that affect any of the
kidney structures, including glomeruli, renal vessels, and
the tubulo-interstitial compartment. Similarly, the dam-
age can be induced by a variety of mechanisms, including
immunologic, metabolic (diabetes), hemodynamic (hy-
pertension), ischemic, and toxic injury. These all trig-
ger renal inflammation that is followed either by tissue
repair or by scarring that destroys individual nephrons.
Typically, 60% to 70% of the nephrons will already have
been destroyed before CRF is diagnosed, and from then
on the damage progresses to ESRF, regardless of the
original cause of injury. This auto-aggravation (progres-
sion) phase is characterized by the development of an
inflammatory process, and by the accumulation of ex-
tracellular matrix (fibrosis) affecting mainly the tubulo-
interstitial compartment [4]. The ensuing decline in renal
function can be slowed by therapies based on angiotensin
II-converting enzyme inhibitors (ACEI) and angiotensin
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II receptor type 1 (AT1) antagonists, but they are only
partially effective, even if drug associations are used [5].
A major challenge is the identification of prognostic
markers that could allow disease progression to be pre-
dicted, and also better monitoring of the effects of reno-
protective therapies by using more accurate targets than
blood pressure levels and urinary protein excretion rates.
In this issue of Kidney International, by employing
DNA array technology followed by expression validation
using real-time polymerase chain reaction (PCR) [6, 7],
Henger et al [8] provide the proof of principle that renal
lesions can be categorized by gene expression profiling.
Even more important, they show that gene expression
profiles established from various nephropathies can al-
low the outcome of renal function to be predicted. To test
gene expression–based renal disease categorization, gene
expression profiles were compared between three control
and nine hydronephrotic kidneys showing varying de-
grees of inflammation and fibrosis. Hydronephrosis was
used as a model of renal disease progression because the
ensuing tubulo-interstitial inflammation and fibrosis are
similar to lesions observed in renal disease progression,
and because if left untreated, it leads to an irreversible
stage of scarring and loss of renal function. Renal biopsy
specimens were categorized using the same cluster al-
gorithm for morphometric and gene expression data.
Segregation of the biopsy specimens between fibrosis,
inflammation, and control could be achieved by expres-
sion profiling of a subset of 31 of 375 known genes rep-
resenting molecules involved in cell-cell contact, matrix
turnover and cytokines, chemokines, and their receptors.
A subgroup of nine of these genes showed a stringent
differential expression by real-time reverse transcription
(RT)-PCR between control and hydronephrotic samples
with fibrosis versus inflammation. Although these results
were obtained in a small number of hydronephrotic kid-
neys, they suggest that gene expression–based classifica-
tion of renal lesions is feasible, and furthermore, that gene
expression profiling may provide important clues to the
pathophysiologic mechanisms involved.
The most fascinating data provided by Henger et al
[8] are the striking correlations that these authors estab-
lished between the expression of the nine genes sorted
out by bioinformatic analysis of gene expression pro-
files of hydronephrotic kidneys, and the outcome of re-
nal function in patients with a range of nephropathies and
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tubulo-interstitial damage. The patients’ biopsies showed
either prominent tubulo-interstitial inflammation or fi-
brosis. The reasons for looser correlation between
histologic and molecular diagnoses in patients with
nephropathies compared to hydronephrosis may be: first,
because the disease process is more complex than in
hydronephrosis and induces a mix of inflammatory and
fibrotic lesions; or second, because the phenotypic char-
acterization of inflammation and fibrosis in the patients
biopsies was not based on immunohistochemical mark-
ers as it was in hydronephrotic kidneys. However, when
patients were analyzed for disease progression, a subset
of genes was able to distinguish between patients with
stable or remittent disease and those requiring renal re-
placement therapy. Although they need to be confirmed
in a larger number of human biopsies, the results re-
ported by Henger et al [8] strongly suggest that renal
disease progression can be molecularly defined by gene
expression fingerprints, which point to the existence of
gene networks specific for this disease stage, irrespec-
tive of the original nephropathy. This important concept
needs to be validated in at least two ways. First, human
renal biopsies only provide a snapshot of the gene ac-
tivation profile when the biopsy was taken and not at
a defined time after the onset of the disease. This lim-
itation does not apply to animal models of human re-
nal diseases. Hopefully, the comparison between animal
models of gene expression profiles obtained at key stages
of renal disease, such as induction of proteinuria, full-
blown injury, inflammation phase, and extracellular ma-
trix expansion, will allow to gene networks specific for
those stages to be identified, and the murine data to be
cross-checked with those established from human biop-
sies. Second, because gene expression profiling does not
reflect protein synthesis, it should be complemented by
urinary and renal tissue proteomic profiling both in hu-
man and in experimental models. The recent develop-
ment of high throughput proteomics technology makes
this approach feasible for renal tissue and will allow the
validation of the functional significance of gene profiling
[9]. Because the day-to-day monitoring of renoprotective
therapies is incompatible with reiterated renal biopsies,
high-throughput urinary proteomics should also be de-
veloped. However, this approach has several technical
and conceptual limitations. The high salt concentration
and the predominance of albumin are among the diffi-
culties that have to be surmounted. More importantly,
the urinary proteome is not likely to faithfully reflect the
renal tissue proteome, and further studies are needed to
characterize the regulation of protein urinary excretion
in diseased nephrons, the sensitivity of excreted proteins
to urinary proteolytic enzymes, and the cellular turnover
and urinary half-life of proteins of interest. Nevertheless,
one can hypothesize that proteomics screening will yield
specific patterns of protein/peptide profiles in the urine
that reflect specific disease states, and particularly disease
progression. If this hypothesis is confirmed, protein chips
could be designed for the urinary diagnosis of disease
progression, which would be a major step further in the
management of renal patients.
Next to its prognosis value, the identification of
gene/protein networks specific for disease progression
will hopefully provide new molecular targets for innova-
tive renoprotective therapies, and more stringent criteria
for disease surveillance than systemic blood pressure and
daily proteinuria.
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